Form 4: BridgeBio Pharma Director Sells Shares
Insider Transaction (Form 4)
Andrea Ellis, a Director of BridgeBio Pharma, Inc., sold 17,167 shares of common stock on July 9, 2026 for $84.00 per share.
Summary
- Option exercise/conversion: acquired 17,167 Common Stock at $16.75 ($287,547) on July 9, 2026; holds 39,746 after (Direct).
- Open-market sale: disposed of 17,167 Common Stock at $84.00 ($1,442,028) on July 9, 2026; holds 22,579 after (Direct).
- Option exercise/conversion: disposed of 17,167 Stock Option (right to buy) on July 9, 2026; holds 17,167 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,442,028 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Andrea Ellis — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Option exercise/conversion | Common Stock | 17,167 | $17 | $287.5K | 39,746 |
| 2026-07-09 | Open-market sale | Common Stock | 17,167 | $84 | $1.4M | 22,579 |
| 2026-07-09 | Option exercise/conversion | Stock Option (right to buy) | 17,167 | — | — | 17,167 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Option exercise/conversion (17,167 shares) |
| 2026-07-09 | Open-market sale (17,167 shares) |
| 2026-07-09 | Option exercise/conversion (17,167 shares) |
Keywords
insider transaction, Form 4, BBIO, BridgeBio Pharma, Inc., bearish, Andrea Ellis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.